CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Kidney Pancreas Transplantation
Interventions
DRUG

Envarsus XR

The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.

Trial Locations (1)

53792

RECRUITING

University of Wisconsin, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

University of Wisconsin, Madison

OTHER